NEWS   RECALLS   COMPLAINT FORM   SCAM ALERTS   RESOURCES
Small Claims Guide   Class Actions   Lemon Laws   FAQ   Newsletters  
Bookmark and Share


Complain about a product or service

Automotive   Education   Employment   Electronics   Family   Finance   Health    Homeowners   Insurance   Pets   Shopping   Travel    Print This     Email This  



NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Lung Cancer Drug Under Fire





March 4, 2005
Iressa, a drug approved to treat non-small cell lung cancer, should be pulled from the market because it does not improve survival rates and has been linked to deaths in Japan and the United States, Public Citizen told the U.S. Food and Drug Administration (FDA).

In a petition that seeks to have the drug pulled from the market, and in testimony delivered to the FDA's Advisory Committee on Oncologic Drugs, Public Citizen said that Iressa should be reclassified as an experimental drug.

Iressa was approved in May 2003 under an accelerated approval program. Because it had been demonstrated only to reduce tumor size, its approval was conditioned on the manufacturer, AstraZeneca, studying the drug further to determine whether it prolonged survival.

That study has been done; patients taking Iressa didn't live any longer than patients taking a placebo.

Rather than pull the drug, however, as the FDA has the authority to do under the accelerated approval process, the agency merely advised patients to consider taking one of two other drugs that - unlike Iressa - have been proven effective in prolonging survival.

Further, Iressa has been linked to deaths. In January, Japanese scientists linked Iressa to a total of 1,473 adverse events and 588 deaths in that country.

In addition, according to a Public Citizen analysis of the FDA's adverse event reactions database, there have been 144 reports of acute interstitial pneumonia in patients taking the drug between May 2003 and September 2004, including 87 deaths for which Iressa was suspected to be the cause.

The continued use of Iressa "puts all patients at risk for a serious and potentially fatal lung disease that is occurring with a relatively high incidence," said Dr. Peter Lurie, deputy director of Public Citizen's Health Research Group.

"Leaving Iressa on the market increases the likelihood that patients will be diverted from an effective therapy to an ineffective therapy, endangering their lives. Keeping a drug on the market while effectively telling people to avoid taking it is not an adequate public health response."



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!

Follow us on Twitter.





CONSUMER NEWS

SAFETY RECALLS

Back to the top |

Advertisement


Custom Search
AUTOMOTIVE
• Dealers
• Manufacturers
• Service
• Extended Warranties
• Lemon Laws
• Recalls
• Tires
• Transporters

FAMILY
• Aging
• Children, Parenting
• Recalls
• Dating
• Education
• Entertainment
• Pets
• Weddings
FINANCE
• Annuities
• Banks
• Credit Cards
• Debt Collection
• Debt Counseling
• Insurance
• Investing
• Loans
• Mortgages
• Payday Loans
• Student Loans
• Tax Prep

HEALTH
• Doctors
• Drugs, Pharmacies
• Health Clubs
• Hearing Care
• Hospitals
• Nursing Homes
• Nutrition, Diets
• Vision Care
• Weight Loss
HOUSE & HOME
• Appliances
• Cookware
• Furniture
• Home Improvements
• Lawn & Garden
• Movers
• Pools & Spas
• Realtors, Rental Agents
• Recalls
• Utilities

ELECTRONICS
• Cable TV/DBS
• Cameras
• Cell Phones
• Computers
• Home Electronics
• Internet Access
• Local Phone Service
• Long Distance
• VoIP
SHOPPING
• Delivery Services
• In-Home
• Online
• Retail Stores
• Sporting Goods
• Supermarkets
• Telemarketers

TRAVEL
• Airlines
• Bus Lines
• Car Rental
• Cruises
• Hotels
• Travel Agents
• Trains

RESOURCES
• Class Actions
• Complaint Form
• Small Claims Guide
• Lemon Laws
CONSUMER NEWS
• Latest News
• Automotive
• Telecom
• Financial
• Health
• Homeowners
• Scams
• Seniors
• Travel
• More ...

RECALLS
• Automotive
• Children's Products
• Drugs
• Food
• Household Products
• Sporting Goods

ABOUT US
• FAQ
• Privacy Policy
• Advertise With Us
• Newsroom
• Syndication
• Terms of Use

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2010 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.